MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) ROCE % : -11.95% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is MoonLake Immunotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MoonLake Immunotherapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -11.95%.

MoonLake Immunotherapeutics ROCE % Historical Data

The historical data trend for MoonLake Immunotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MoonLake Immunotherapeutics ROCE % Chart

MoonLake Immunotherapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-225.23

-18.48

MoonLake Immunotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial						-88.02	-80.39	-18.87	-10.49	-11.95

MoonLake Immunotherapeutics ROCE % Calculation

MoonLake Immunotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-54.123	/	( ( (76.843 - 7.665)	+	(526.54 - 9.966) )	/ 2 )
	=	-54.123	/	( (69.178	+	516.574)	/ 2 )
	=	-54.123	/	292.876
	=	-18.48 %

MoonLake Immunotherapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-60.116	/	( ( (500.219 - 10.308)	+	(526.54 - 9.966) )	/ 2 )
	=	-60.116	/	( ( 489.911	+	516.574 )	/ 2 )
	=	-60.116	/	503.2425
	=	-11.95 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

MoonLake Immunotherapeutics (NAS:MLTX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MoonLake Immunotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of MoonLake Immunotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MoonLake Immunotherapeutics (MoonLake Immunotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MoonLake Immunotherapeutics (NAS:MLTX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MLTX:Mexico

Address

Dorfstrasse 29, Zug, CHE, 6300

Website

https://www.moonlaketx.com

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Executives

Matthias Bodenstedt	officer: Chief Financial Officer	DORFSTRASSE 29, ZUG V8 6300
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iv Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Private Healthcare Fund Ii, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Simon Sturge	director	DORFSTRASSE 29, ZUG V8 6300
Kristian Reich	officer: Chief Scientific Officer	DORFSTRASSE 29, ZUG V8 6300
Santos Da Silva Jorge	director, officer: Chief Executive Officer	DORFSTRASSE 29, ZUG V8 6300
Bvf Partners L P/il	director, 10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Andrew John Phillips	director	C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET, FL 52, BOSTON MA 02116
Ramnik Xavier	director	DORFSTRASSE 29, ZUG V8 6300
Spike Loy	director	DORFSTRASSE 29, ZUG V8 6300
Kara Lassen	director	DORFSTRASSE 29, ZUG V8 6300